27 min read
Keypoint Newsletter: Welcoming the New Fellows Class of 2024
Keystone Symposia is pleased to introduce the Keystone Symposia Fellows Class of 2024! This year we welcome seven...
Jonathan Deane earned his B.S. and Ph.D. at the University of California, Irvine. His graduate student work was focused on the role of regulatory subunits of the lipid kinase PI3K in immune and leukemia function. At the NIAID, his postdoctoral fellowship was concentrated on the role of nucleic acid-sensing receptors in the innate immune system. Specifically, he focused on TLR7 and MDA5 to understand that expression levels of these molecules contributes to the development of autoimmune disease. As an investigator at the Genomics Institute of the Novartis Research Foundation, Jonathan spent over 10 years in drug discovery considering ways to apply basic research to making novel therapeutics. This led to the nomination of 3 clinical candidates including LHC165, an intratumoral TLR7 agonist. He also helped outlicense IOV-3001, a novel IL-2 biologic which is now being developed by Iovance. Since July 2020, Jonathan has been the Director of Immunology at Kumquat Biosciences, a startup company dedicated to developing novel therapeutics in the fields of oncology, immune oncology and immunology.
Research Area(s):
CancerResearch Keywords:
Mentor: Robert L. Coffman, PhD
Dec 4, 2023 by Keystone Symposia
Keystone Symposia is pleased to introduce the Keystone Symposia Fellows Class of 2024! This year we welcome seven...
Sep 6, 2023 by Keystone Symposia
Established in 2009, Keystone Symposia’s Fellows Program has become a premier professional advancement opportunity for...